Vertex Pharmaceuticals
VRTX
1,106 hedge funds and large institutions have $65.6B invested in Vertex Pharmaceuticals in 2022 Q2 according to their latest regulatory filings, with 132 funds opening new positions, 360 increasing their positions, 440 reducing their positions, and 78 closing their positions.
69% more first-time investments, than exits
New positions opened: 132 | Existing positions closed: 78
33% more funds holding in top 10
Funds holding in top 10: 24 → 32 (+8)
8% more capital invested
Capital invested by funds: $60.8B → $65.6B (+$4.87B)
3% more funds holding
Funds holding: 1,071 → 1,106 (+35)
0.43% less ownership
Funds ownership: 92.43% → 91.99% (-0.43%)
3% less call options, than puts
Call options by funds: $468M | Put options by funds: $480M
18% less repeat investments, than reductions
Existing positions increased: 360 | Existing positions reduced: 440
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$956M |
| 2 |
Jennison Associates
New York
|
+$381M |
| 3 |
BlackRock
New York
|
+$327M |
| 4 |
Morgan Stanley
New York
|
+$268M |
| 5 |
Massachusetts Financial Services
Boston,
Massachusetts
|
+$221M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Loomis, Sayles & Company
Boston,
Massachusetts
|
-$517M |
| 2 |
AllianceBernstein
Nashville,
Tennessee
|
-$336M |
| 3 |
ClearBridge Investments
New York
|
-$243M |
| 4 |
AWA
Aaron Wealth Advisors
Chicago,
Illinois
|
-$158M |
| 5 |
D.E. Shaw & Co
New York
|
-$125M |
VRTX Hedge Fund Activity: Q2 2022 in Review
1,106 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in Vertex Pharmaceuticals (VRTX) for Q2 2022, worth a combined $65.6B — up 8% from $60.8B a quarter earlier.
Buyers outnumbered sellers: 132 funds opened new VRTX positions and 78 closed out — a net gain of 54 holders — while 360 added to existing stakes and 440 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $956M. The largest seller was Loomis, Sayles & Company, cutting an estimated $517M.
- 1,106 institutional investors held Vertex Pharmaceuticals (VRTX) as of Q2 2022, up from 1,071 in Q1 2022.
- Funds reported $65.6B of Vertex Pharmaceuticals stock for Q2 2022, up 8% quarter-over-quarter.
- 132 funds opened new Vertex Pharmaceuticals positions in Q2 2022 and 78 closed out, a net change of +54 holders.
- The largest Vertex Pharmaceuticals buyer in Q2 2022 was Fidelity Investments, an estimated $956M added.
- The largest Vertex Pharmaceuticals seller in Q2 2022 was Loomis, Sayles & Company, an estimated $517M sold.
Based on aggregated 13F filings for Q2 2022.